Imaging and liquid biopsy for glioma diagnosis and treatment monitoring

Ended Project Grant Awarded Last action

Award ID
R01CA239078
Recipient
Awarding agency
Obligated
$7,317,793

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date
Originally
Funding
  • $6,682,394.00 Federal
  • $635,399.00 Non-federal
Place of performance
Massachusetts, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $30,452 $0
Amendment $30,452 $0
Amendment $548,141 $0
Amendment $548,141 $0
Amendment $548,141 $0
Amendment $605,638 $0
Amendment $605,638 $0
Amendment $605,638 $0
Amendment $50,146 $0
Amendment $50,146 $0
Amendment $564,107 $0
Amendment $564,107 $0
Amendment $635,399 $0
Amendment $635,399 $635,399
Original award $660,849 $0
Show all 18

Subawards

Subrecipient Amount Awarded
Exosome Diagnostics Inc. The main objective of this collaborative proposal is to apply a liquid biopsy platform for the analysis of extracellular vesicles (EVs), in a bid to monitor the… $209,273

Quick answers

Who received award R01CA239078?

R01CA239078 was awarded to The General Hospital Corporation by National Cancer Institute (National Institutes of Health) on March 1, 2020.

How much is award R01CA239078 worth?

$7,317,793 has been obligated on R01CA239078: $6,682,394 in federal funding and $635,399 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award